Switch theme
Sign up to access all valuation multiples
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.
2018
869
LTM Revenue $486M
LTM EBITDA $50.7M
$522M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Organogenesis has a last 12-month revenue (LTM) of $486M and a last 12-month EBITDA of $50.7M.
In the most recent fiscal year, Organogenesis achieved revenue of $482M and an EBITDA of $15.8M.
Organogenesis expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Organogenesis valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $486M | XXX | $482M | XXX | XXX | XXX |
| Gross Profit | $374M | XXX | $366M | XXX | XXX | XXX |
| Gross Margin | 77% | XXX | 76% | XXX | XXX | XXX |
| EBITDA | $50.7M | XXX | $15.8M | XXX | XXX | XXX |
| EBITDA Margin | 10% | XXX | 3% | XXX | XXX | XXX |
| EBIT | $2.8M | XXX | $21.5M | XXX | XXX | XXX |
| EBIT Margin | 1% | XXX | 4% | XXX | XXX | XXX |
| Net Profit | $1.9M | XXX | $0.9M | XXX | XXX | XXX |
| Net Margin | 0% | XXX | 0% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 1, 2025, Organogenesis's stock price is $4.
Organogenesis has current market cap of $464M, and EV of $522M.
See Organogenesis trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $522M | $464M | XXX | XXX | XXX | XXX | $0.03 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 1, 2025, Organogenesis has market cap of $464M and EV of $522M.
Organogenesis's trades at 1.1x EV/Revenue multiple, and 33.1x EV/EBITDA.
Equity research analysts estimate Organogenesis's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Organogenesis has a P/E ratio of 247.8x.
See valuation multiples for Organogenesis and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $464M | XXX | $464M | XXX | XXX | XXX |
| EV (current) | $522M | XXX | $522M | XXX | XXX | XXX |
| EV/Revenue | 1.1x | XXX | 1.1x | XXX | XXX | XXX |
| EV/EBITDA | 10.3x | XXX | 33.1x | XXX | XXX | XXX |
| EV/EBIT | 183.8x | XXX | 24.3x | XXX | XXX | XXX |
| EV/Gross Profit | 1.4x | XXX | n/a | XXX | XXX | XXX |
| P/E | 247.8x | XXX | 539.2x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 125.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialOrganogenesis's last 12 month revenue growth is 5%
Organogenesis's revenue per employee in the last FY averaged $0.6M, while opex per employee averaged $0.4M for the same period.
Organogenesis's rule of 40 is 13% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Organogenesis's rule of X is 23% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Organogenesis and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 5% | XXX | 5% | XXX | XXX | XXX |
| EBITDA Margin | 10% | XXX | 3% | XXX | XXX | XXX |
| EBITDA Growth | 18% | XXX | 20% | XXX | XXX | XXX |
| Rule of 40 | 13% | XXX | 8% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 23% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.6M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.4M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 10% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 72% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Lineage Cell Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Arovella Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Aroa Biosurgery | XXX | XXX | XXX | XXX | XXX | XXX |
| Cynata Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Mesoblast | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Organogenesis acquired XXX companies to date.
Last acquisition by Organogenesis was XXXXXXXX, XXXXX XXXXX XXXXXX . Organogenesis acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Organogenesis founded? | Organogenesis was founded in 2018. |
| Where is Organogenesis headquartered? | Organogenesis is headquartered in United States of America. |
| How many employees does Organogenesis have? | As of today, Organogenesis has 869 employees. |
| Who is the CEO of Organogenesis? | Organogenesis's CEO is Mr. Gary S. Gillheeney, Sr. |
| Is Organogenesis publicy listed? | Yes, Organogenesis is a public company listed on NAS. |
| What is the stock symbol of Organogenesis? | Organogenesis trades under ORGO ticker. |
| When did Organogenesis go public? | Organogenesis went public in 2016. |
| Who are competitors of Organogenesis? | Similar companies to Organogenesis include e.g. Lineage Cell Therapeutics, Arovella Therapeutics, Aroa Biosurgery, Cynata Therapeutics. |
| What is the current market cap of Organogenesis? | Organogenesis's current market cap is $464M |
| What is the current revenue of Organogenesis? | Organogenesis's last 12 months revenue is $486M. |
| What is the current revenue growth of Organogenesis? | Organogenesis revenue growth (NTM/LTM) is 5%. |
| What is the current EV/Revenue multiple of Organogenesis? | Current revenue multiple of Organogenesis is 1.1x. |
| Is Organogenesis profitable? | Yes, Organogenesis is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Organogenesis? | Organogenesis's last 12 months EBITDA is $50.7M. |
| What is Organogenesis's EBITDA margin? | Organogenesis's last 12 months EBITDA margin is 10%. |
| What is the current EV/EBITDA multiple of Organogenesis? | Current EBITDA multiple of Organogenesis is 10.3x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
